Showing results (1-10 of 30) with videos related to
Sort By:
Pageof 3
Expert Opinion on Investigational Drugs|July 23, 2004
5th Antiviral Drug Discovery and Development SummitWade Blair, Manos PerrosExpert Opinion on Drug Discovery|March 19, 2013
CCR5 inhibitors in HIV-1 therapyPatrick Dorr, Manos PerrosDrug Discovery Today|February 21, 2021
Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibioticsDavid Altarac, Michael Gutch, John Mueller, et al.Antimicrobial Agents and Chemotherapy|February 3, 2016
Untargeted Metabolomics To Ascertain Antibiotic Modes of ActionIsabel M Vincent, David E Ehmann, Scott D Mills, et al.Antiviral Research|September 15, 2005
Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor densitySamantha Willey, Paul J Peters, W Matthew Sullivan, et al.Bioorganic & Medicinal Chemistry Letters|August 28, 2009
Pyrazole NNRTIs 1: design and initial optimisation of a novel templateCharles E Mowbray, Catherine Burt, Romuald Corbau, et al.Journal of Virology|December 22, 2006
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entryMike Westby, Caroline Smith-Burchnell, Julie Mori, et al.Bioorganic & Medicinal Chemistry Letters|June 20, 2006
Overcoming HERG affinity in the discovery of the CCR5 antagonist maravirocDavid A Price, Duncan Armour, Marcel de Groot, et al.Current Topics in Medicinal Chemistry|September 11, 2008
Overcoming hERG affinity in the discovery of maraviroc; a CCR5 antagonist for the treatment of HIVDavid A Price, Duncan Armour, Marcel de Groot, et al.Chemical Biology & Drug Design|April 25, 2006
The discovery of tropane-derived CCR5 receptor antagonistsDuncan R Armour, Marcel J de Groot, David A Price, et al.Pageof 3